Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
3201
-
3202
-
3203
-
3204
-
3205
-
3206
-
3207
-
3208
-
3209
-
3210
Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
3211
Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
3212
Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019.
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
3213
Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0).
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
3214
Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
3215
Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription.
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
3216
UTI diagnoses by sex and physician specialty (2013–2019).
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
3217
-
3218
-
3219
Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX
Published 2024“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
-
3220
Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX
Published 2024“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”